INmune Bio fails to meet main goal in Alzheimer's treatment study

June 30, 2025 06:16 AM PDT | By EODHD

Google News:

INmune Bio fails to meet main goal in Alzheimer's treatment study — Image source: Kalkine Media

Recent News

Nike Lifts Dow Jones Industrial Average as Consumer Services and Indus...

BioRobotics Sees Activity Amid NASDAQ Composite Movement

Why ADBE Faces Scrutiny Creative Strength and S&P 500 Inclusion

Zions Bancorporation N.A a Russell 1000 Member

[Alzheimers Concept Horizontal] travellinglight/iStock via Getty Images Shares of INmune Bio (NASDAQ:INMB [https://seekingalpha.com/symbol/INMB]) dropped on Monday after the company did not achieve the main goal in a mid-stage trial for its TNF inhibitor, XPro, aimed at treating early Alzheimer’s Disease. In the trial involving 200 patients, XPro did not meet the key goal of change in cognition over 6 months in a cognitive assessment designed specifically to measure change in early Alzheimer’s Disease patients. However, the company said [https://seekingalpha.com/pr/20151504-inmune-bio-reports-key-findings-from-phase-2-mindful-trial-of-xpro-in-early-alzheimer-s]that in a specific group of early Alzheimer’s patients who tested positive for amyloid and had two or more signs of inflammation, XPro showed benefits compared to a placebo in areas related to thinking, behavior, and biological markers. XPro treatment was found to be safe and well-tolerated, even among high-risk patients, and no cases of ARIA-E or ARIA-H were reported. The most frequent side effects were reactions at the injection site.

The stock is down 62% premarket. MORE ON INMUNE BIO * INmune Bio: Finding Pay Dirt In Alzheimer's? [https://seekingalpha.com/article/4797869-inmune-bio-finding-pay-dirt-in-alzheimers] * INmune Bio: Imminent Phase 2 Alzheimer's Readout Of Unique Asset Presents Interesting Speculative Opportunity [https://seekingalpha.com/article/4795179-inmune-bio-imminent-phase-2-alzheimers-readout-presents-opportunity] * INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity [https://seekingalpha.com/article/4787329-inmune-bio-xpro-trial-readout-in-alzheimers-disease-offers-big-opportunity] * INmune Bio reverses early gains after stock offering [https://seekingalpha.com/news/4463366-inmune-bio-stock-falls-stock-offering] * INmune Bio surges ahead of mid-stage trial readout for Alzheimer’s drug [https://seekingalpha.com/news/4463250-inmune-bio-surges-ahead-of-mid-stage-trial-readout-for-alzheimer-s-drug]

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.